Thelansis

 Acute graft-versus-host disease (GVHD) is a reaction of donor immune cells against host tissues that occur after an allogeneic hematopoietic stem cell transplant. After an inflammatory cascade that starts with the preparative regimen, activated donor T cells, damage host epithelial cells. Acute GVHD affects approximately 35–50% of hematopoietic stem cell transplant (HSCT) recipients. The specific risk is determined by the stem cell source, patient age, conditioning, and GVHD prophylaxis used. The number and extent of organ involvement in acute GVHD are staged and graded (grade 0-IV). Patients with acute GVHD of grade III/IV have a poor prognosis. The patient is generally treated by improving their immunosuppression and supplementing with methylprednisolone. Methylprednisolone will be effective in about half of the patients. If patients do not improve after three days or if they do not improve after seven days, they will receive salvage (second-line) immunosuppressive therapy, for ...

  After an allogeneic hematopoietic stem cell transplant, acute graft-versus-host disease (GVHD) is a reaction of donor immune cells against host tissues. After an inflammatory cascade that starts with the preparative regimen, activated donor T cells, damage host epithelial cells. Acute GVHD affects approximately 35–50% of hematopoietic stem cell transplant (HSCT) recipients. The specific risk is determined by the stem cell source, patient age, conditioning, and GVHD prophylaxis. The number and extent of organ involvement in acute GVHD are staged and graded (grade 0-IV). Patients with acute GVHD of grade III/IV have a poor prognosis. The patient is generally treated by improving their immunosuppression and supplementing with methylprednisolone. Methylprednisolone will be effective in about half of the patients. If patients do not improve after three days or if they do not improve after seven days, they will receive salvage (second-line) immunosuppressive therapy, for which there is...